Merck's Keytruda Secures Pivotal FDA Approval in Gastric Cancer, Extending Blockbuster Dominance
In a significant advancement for immuno-oncology, Merck & Co. (NYSE: MRK) revealed on March 11, 2026, that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Keytruda (pembrolizumab) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. This approval, based on data from the phase 3 KEYNOTE-585 trial, represents the ninth indication for Keytruda in tumors of the upper gastrointestinal tract, further solidifying its position as the world's top-selling cancer drug.
Clinical Trial Data Underpinning the Approval
The KEYNOTE-585 trial, a randomized, double-blind, placebo-controlled study involving 997 patients, demonstrated statistically significant improvements in pathologic complete response (pCR) rates. Keytruda plus chemotherapy achieved a pCR rate of 13.7% compared to 9.5% with chemotherapy alone (p=0.007). This endpoint served as the basis for the accelerated approval, with overall survival (OS) and event-free survival (EFS) data supporting the benefit, showing hazard ratios of 0.81 (95% CI: 0.70-0.94) and 0.84 (95% CI: 0.73-0.97), respectively.
These results align with Keytruda's established efficacy profile across 40+ approved indications. In 2025, Keytruda generated $25.8 billion in global revenue, up 18% year-over-year, accounting for over 40% of Merck's total sales. The gastric cancer approval targets a market segment with approximately 27,000 new U.S. cases annually, where HER2-positive tumors comprise 15-20% of diagnoses.
Market Reaction and Valuation Implications
Merck's shares reacted positively, climbing 2.1% in premarket trading on March 12 to $112.45, extending a three-day gain of 4.2%. Year-to-date, MRK stock has outperformed the S&P 500 Biotech Select Industry Index by 12%, trading at a forward P/E of 14.2x, a 25% discount to peers like Bristol-Myers Squibb (BMY) and Regeneron (REGN).
Analysts from JPMorgan and BofA Securities raised price targets post-approval, with consensus now at $128, implying 14% upside. The label expansion is projected to add $500-800 million in peak annual U.S. sales by 2028, per Evaluate Pharma estimates, helping offset the anticipated 2028 patent cliff when generic competition could erode 70-80% of Keytruda's U.S. market share.
Strategic Context in Merck's Oncology Portfolio
Keytruda remains the cornerstone of Merck's oncology franchise, which contributed 45% of the company's $60.1 billion in 2025 revenue. Recent setbacks, including the phase 3 KEYNOTE-867 trial failure in NSCLC perioperative setting announced in January 2026, underscore the drug's maturing label. However, this gastric win mitigates risks, particularly as Merck advances next-gen assets like MK-1084, a next-generation PD-1 inhibitor entering phase 3 trials.
Merck's R&D spend hit $13.6 billion in 2025, focused on expanding Keytruda combinations and novel modalities. The company's 2026 guidance projects Keytruda sales of $29-30 billion, with ex-U.S. growth at 20% driven by approvals in China and Europe. This gastric indication follows EMA approval in February 2026, enhancing global reach.
Competitive Landscape in HER2-Positive Gastric Cancer
Gastric cancer therapeutics have evolved rapidly, with HER2-targeted therapies dominating. Roche's Herceptin (trastuzumab) and Enhertu (trastuzumab deruxtecan) from Daiichi Sankyo/AstraZeneca lead the space, with Enhertu posting $2.8 billion in 2025 sales post its 2024 gastric approval. Keytruda's entry introduces an immuno-oncology option, potentially capturing 20-25% market share in first-line HER2-positive settings, where current standards yield median OS of 12-14 months.
Enhertu: ADC with 5.5% pCR in DESTINY-Gastric01; $3.2B projected 2026 sales.
Cyramza (Ramucirumab): Eli Lilly's VEGF inhibitor; combo with paclitaxel standard in second-line.
Keytruda: Now positioned for broader PD-L1 agnostic use in HER2+ via KEYNOTE-585.
Merck's data suggest additive benefit in HER2+ patients, irrespective of PD-L1 status, differentiating it from prior approvals limited to CPS ≥10.
Broader Biotech Sector Implications
This approval arrives amid a biotech rally, with the XBI ETF up 8% in the past week on M&A optimism. Valuation multiples for large-cap biotech have compressed to 3.5x sales from 4.8x in 2025 peaks, favoring cash-generative leaders like Merck. Peers such as Exelixis (EXEL) and Incyte (INCY) reported trial updates, but Merck's news dominates due to Keytruda's scale.
Investor focus shifts to Merck's March 25 Investor Day, where pipeline prioritization will be detailed. Winnowing non-core assets, including recent divestitures of animal health units, bolsters the balance sheet with $14.2 billion in cash equivalents.
Risk Factors and Forward Outlook
Despite bullish signals, headwinds persist. Keytruda's U.S. patent expires in 2028, with biosimilars from Samsung Bioepis and Celltrion slated for launch. Merck's subcutaneous formulation, approved in 2025, aims to retain loyalty, while 50+ ongoing trials could yield 10 new indications by 2030.
Macro pressures, including potential U.S. drug pricing reforms under the Inflation Reduction Act extensions, pose margin risks. Merck's operating margin of 38% in Q4 2025 provides cushion, with EPS guidance of $8.30-8.50 for 2026.
Investment Thesis
Merck remains a core holding for biotech exposure, blending defensive growth with innovation. The gastric approval de-risks near-term revenue, supporting a total return profile of 10-12% annualized through 2028. At current levels, MRK offers asymmetric upside, particularly if M&A accelerates in ADCs or radiopharma.
Market participants should monitor Q1 earnings on April 29 for uptake metrics. With oncology comprising 60% of the late-stage pipeline, Merck's trajectory points to sustained leadership in a $200 billion global cancer market by 2030.
In summary, this FDA milestone not only extends Keytruda's commercial runway but reaffirms Merck's strategic execution in biotechnology's most lucrative segment. Investors positioning for resilient growth would do well to note this development as a bullish catalyst.
